Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Recap: Adaptimmune Therapeutics Q1 Earnings
12:55pm, Thursday, 14'th May 2020
Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.04), w
Adaptimmune Reports Q1 Financial Results
11:30am, Thursday, 14'th May 2020
- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug.
- Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for.
What Kind Of Share Price Volatility Should You Expect For Adaptimmune Therapeutics plc (NASDAQ:ADAP)?
10:07am, Tuesday, 12'th May 2020
If you own shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) then it's worth thinking about how it contributes to...
Should coaches be paid for a canceled season?
12:00pm, Sunday, 10'th May 2020
School districts in Maine have been wrestling with the dilemma, balancing financial concerns with the desire to reward coaches for work they do with student-athletes throughout the year.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Volkswagen Golf GTI TCR: Pricing and arrival date announced
06:30pm, Sunday, 03'rd May 2020
After its reveal at the 2019 Festival of Motoring, Volkswagen South Africa has confirmed 300 units of the Golf GTi TCR will arrive towards the end of July.
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
02:29am, Friday, 01'st May 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Corvus Pharmaceuticals (CRVS) yesterday and set a price target of $7.00. The company's
Corvus Pharmaceuticals (CRVS) Receives a Buy from Mizuho Securities
02:29am, Friday, 01'st May 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Corvus Pharmaceuticals (
CRVS
–
Research Report
) yesterday and set a price target of
$7.00
. The company’s shares closed last T
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
09:05pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX) today and set a price target of $16.00. The company's
Mizuho Securities Sticks to Their Buy Rating for CytomX Therapeutics (CTMX)
09:05pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on CytomX Therapeutics (CTMX – Research Report) today and set a
BRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-Q
01:23pm, Wednesday, 29'th Apr 2020
Adaptimmune Therapeutics PLC:
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
01:07pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE) today and set a price target of $40.00. The company's shares
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
01:07pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
12:00pm, Wednesday, 29'th Apr 2020
- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP),.
